The Venture Codex Logo

The Venture Codex

Monograph Capital

Duo, Level 6, 280 Bishopsgate, London, Greater London, EC2M 4RB, United Kingdom

Overview

Venture firm funding groundbreaking life sciences companies.

Founded

2021

Deals · 12mo

5

Links

WebsiteLinkedIn

Stage focus

Series A
Series B

Geographic focus

Singapore
United Kingdom
United States

Sector focus

—

Investment portfolio

15rounds
NAMEDATESIZE
Ollin Biosciences
Jun 2026Participated
$330 MSeries B
RQ Bio
Jun 2026Participated
$115 MSeries A
Nocion Therapeutics
Jan 2026Led
$23 MSeries B
Prolynx
Dec 2025Participated
$70 MSeries A
Elevara Medicines
Oct 2025Participated
$70 MSeries A
Ollin Biosciences
Sep 2025Led
$100 MSeries A
Maxion Therapeutics
Mar 2025Participated
$78 MSeries A
Ouro Medicines
Jan 2025Participated
$120 MSeries A
Autobahn Therapeutics
Jul 2024Participated
$100 MSeries C
Nocion Therapeutics
Mar 2024Led
$62 MSeries B
Maxion Therapeutics
Feb 2023Led
$16 MSeries A
RegASK
Dec 2022Led
$10 MSeries A
Ollin Biosciences
Jun 2026Participated
$330 MSeries B
RQ Bio
Jun 2026Participated
$115 MSeries A
Nocion Therapeutics
Jan 2026Led
$23 MSeries B
Prolynx
Dec 2025Participated
$70 MSeries A
Elevara Medicines
Oct 2025Participated
$70 MSeries A
Ollin Biosciences
Sep 2025Led
$100 MSeries A
Maxion Therapeutics
Mar 2025Participated
$78 MSeries A
Ouro Medicines
Jan 2025Participated
$120 MSeries A
Autobahn Therapeutics
Jul 2024Participated
$100 MSeries C
Nocion Therapeutics
Mar 2024Led
$62 MSeries B
Maxion Therapeutics
Feb 2023Led
$16 MSeries A
RegASK
Dec 2022Led
$10 MSeries A
15
Items
...
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Monograph Capital: 15 funding rounds are recorded in the selected participation categories.All available history.
Monograph Capital: 15 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series A45
Series B22
Series C+01
Other Equity01

Monthly Deal Activity

Monograph Capital: 15 deals are recorded across 59 months.All available history.
Monograph Capital: 15 deals are recorded across 59 months. All available history
MonthDeals
Dec '211
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '221
Jul '220
Aug '220
Sep '220
Oct '220
Nov '221
Dec '221
Jan '230
Feb '231
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '241
Apr '240
May '240
Jun '240
Jul '241
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '251
Feb '250
Mar '251
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '251
Oct '251
Nov '250
Dec '251
Jan '261
Feb '260
Mar '260
Apr '260
May '260
Jun '262
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Monograph Capital: Health & Life Sciences is the largest displayed sector by deal count (14 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Monograph Capital: Health & Life Sciences is the largest displayed sector by deal count (14 deals). All available history
SectorDeals
Health & Life Sciences14
Enterprise Software1
Manufacturing1
Professional Services1
Consumer & Lifestyle1

Deal Size Distribution

Monograph Capital: 15 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Monograph Capital: 15 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M3
$25M-$50M0
$50M-$100M6
$100M-$250M5
$250M-$500M1
$500M-$1B0
$1B+0

Deals By Geography

Monograph Capital: United States has the largest recorded deal count among the displayed regions (8 deals).All available history.

Top 3 of 3 regions; European countries are grouped as Europe.

Monograph Capital: United States has the largest recorded deal count among the displayed regions (8 deals). All available history
RegionDeals
United States8
Europe6
Singapore1
Monograph Capital: 20 co-investors are shown, with ARCH Venture Partners sharing 4 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Monograph Capital: 20 co-investors are shown, with ARCH Venture Partners sharing 4 recorded deals. All available history
Co-investorShared deals
ARCH Venture Partners4
Canaan Partners3
F-Prime Capital3
LifeArc3
Advent Life Sciences2
Arkin Bio Ventures2
BGF2
EQT Life Sciences (LSP)2
Forbion2
Mass General Brigham Ventures2
Mission BioCapital2
Mubadala Capital2
New Enterprise Associates2
OrbiMed2
Osage University Partners2
Oxford Science Enterprises2
Samsara BioCapital2
5AM Ventures1
a16z Bio + Health1
Alexandria Venture Investments1

Investment Strategy

Monograph Capital: Led accounts for 40% and participating for 60% of round participation.All available history.
Monograph Capital: Led accounts for 40% and participating for 60% of round participation. All available history
CategoryDeals (count)Share (%)
Led640%
Participating960%
Monograph Capital: Single-lead accounts for 17% and co-led for 83% of lead dynamics.All available history.
Monograph Capital: Single-lead accounts for 17% and co-led for 83% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead117%
Co-led583%

Team

Bonnie van Wilgenburg

Principal

Charles Conn

Co-founder

Fred Cohen

Co-Founder & Sr. Managing Director

Tim Funnell

Partner

Travis Murdoch

Partner